Bextra (valdecoxib) and rare skin diseases
Saturday November 20, 2004
Dr. David Graham, a scientist for the U.S. Food and Drug Administration (FDA), gave expert testimony before a U.S. Senate committee on Thursday, November 18, 2004. During his testimony he stated that the FDA should focus its attention on Bextra (valdecoxib), marketed by Pfizer, due to deaths it has caused. Those fatalities were due to Stevens-Johnson syndrome and toxic epidermal necrolysis, two rare but potentially fatal skin disorders that are caused by reactions to certain medications.
In Stevens-Johnson syndrome, the mucous membranes of the mouth, throat, digestive tract, and eyes become inflamed and may blister and bleed. In toxic epidermal necrolysis, large areas of blisters appear on the skin, which then peels and sloughs off. The mucous membranes may also become inflamed and blistered. Either disorder may be fatal if not recognized promptly and treated.
Comments
Stevens Johnson Syndrome and Bextra has also become the topic of lawsuits.
If you have taken Bextra and since developed Stevens Johnson Syndrome, you will most likely be entitled to compensation.
Here is a good Bextra Stevens Johnson Syndrome lawsuit resource: Bextra Stevens Johnson Syndrome